Raphael Pharmaceutical Inc.
For the period ended Jun 30, 2025. Filed Aug 13, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Jun 30, 2025 · Filed Aug 13, 2025
RAPHStored price and day change unavailable
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Interim Statements of Cash Flows
| 2025 · 2024 | ||||
|---|---|---|---|---|
| Cash flows from operating activities | ||||
| Net loss | $(751) | $(798) | ||
| Adjustments to reconcile net loss to net cash used in operating activities: | ||||
| Share-based payment in exchange for services | 205 | 61 | ||
| Depreciation | (* | ) | (* | ) |
| Changes in: | ||||
| Other current assets | (2) | 1 | ||
| Related parties | 336 | - | ||
| Account payables and accrued expenses | (27) | 346 | ||
| Net cash used in operating activities | (239) | (390) | ||
| Cash flows from financing activities | ||||
| Issuance of common stock and warrants | 240 | 280 | ||
| Advance payment on account of shares | - | - | ||
| Net cash provided by financing activities | 240 | 280 | ||
| Change in cash and cash equivalents | 1 | (110) | ||
| Cash and cash equivalents at the beginning of the period | 19 | 230 | ||
| Cash and cash equivalents at the end of the period | $20 | $120 | ||
| (*) | Less than 1 thousand. |
|---|
| ** | During the reporting period, 350,000 shares and 450,000 warrants were granted to 2 directors in exchange for their services. |
|---|
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.